Invalid Symbol

Stock Research for RGLS

RGLS
Current Price

$


Latest Update:

High
$
Low
$
Close
$
Volume
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

RGLS Stock Chart & Research Data

The RGLS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RGLS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


RGLS Due diligence Resources & Stock Charts

The RGLS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View RGLS Detailed Price Forecast - CNN Money CNN View RGLS Detailed Summary - Google Finance
Yahoo View RGLS Detailed Summary - Yahoo! Finance Zacks View RGLS Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View RGLS Trends & Analysis - Trade-Ideas Barrons View RGLS Major Holders - Barrons
NASDAQ View RGLS Call Transcripts - NASDAQ Seeking View RGLS Breaking News & Analysis - Seeking Alpha
Spotlight View RGLS Annual Report - CompanySpotlight.com OTC Report View RGLS OTC Short Report - OTCShortReport.com
TradeKing View RGLS Fundamentals - TradeKing Charts View RGLS SEC Filings - Bar Chart
WSJ View Historical Prices for RGLS - The WSJ Morningstar View Performance/Total Return for RGLS - Morningstar
MarketWatch View the Analyst Estimates for RGLS - MarketWatch CNBC View the Earnings History for RGLS - CNBC
StockMarketWatch View the RGLS Earnings - StockMarketWatch MacroAxis View RGLS Buy or Sell Recommendations - MacroAxis
Bullish View the RGLS Bullish Patterns - American Bulls Short Pains View RGLS Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View RGLS Stock Mentions - StockTwits PennyStocks View RGLS Stock Mentions - PennyStockTweets
Twitter View RGLS Stock Mentions - Twitter Invest Hub View RGLS Investment Forum News - Investor Hub
Yahoo View RGLS Stock Mentions - Yahoo! Message Board Seeking Alpha View RGLS Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for RGLS - SECform4.com Insider Cow View Insider Transactions for RGLS - Insider Cow
CNBC View RGLS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for RGLS - OTC Markets
Yahoo View Insider Transactions for RGLS - Yahoo! Finance NASDAQ View Institutional Holdings for RGLS - NASDAQ


Stock Charts

FinViz View RGLS Stock Insight & Charts - FinViz.com StockCharts View RGLS Investment Charts - StockCharts.com
BarChart View RGLS Stock Overview & Charts - BarChart Trading View View RGLS User Generated Charts - Trading View


Latest Financial News for RGLS

Regulus to Participate in the LEERINK Partners 7th Annual Global Healthcare Conference
Posted on Thursday February 08, 2018

Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.


Analysis: Positioning to Benefit within Churchill Downs, Airgain, Fortune Brands Home & Security, Kemper, Perficient, and Regulus Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results
Posted on Friday January 05, 2018

NEW YORK, Jan. 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Churchill ...


Regulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
Posted on Tuesday December 19, 2017

LA JOLLA, Calif. , Dec. 19, 2017 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, ...


Edited Transcript of RGLS earnings conference call or presentation 7-Nov-17 10:00pm GMT
Posted on Monday November 13, 2017

Q3 2017 Regulus Therapeutics Inc Earnings Call


Buy Consensus rating Stock: Regulus Therapeutics Inc. (RGLS)
Street Observer (press release) - Nov 20, 2017
Regulus Therapeutics Inc. (RGLS) stock price traded with dropping change along with the volume 0.54 million shares on Friday trading session.

EPS for Regulus Therapeutics Inc. (RGLS) Expected At $-0.15
BZ Weekly - 12 hours ago
Barclays Public Limited Company stated it has 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Macquarie Group Inc holds 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS) or 20,000 shares. Moreover, Bvf Incorporated Il has 2.06% invested in Regulus ...
Regulus Therapeutics Inc. (RGLS) EPS Estimated At $-0.15 - Reurope

Regulus Therapeutics Inc. (RGLS) Soars 6.9% on February 13
Equities.com - Feb 13, 2018
Regulus Therapeutics Inc. (RGLS) had a good day on the market for Tuesday February 13 as shares jumped 6.9% to close at $1.24.
Regulus Therapeutics Inc: Sanofi Disclosed Stake - BZ Weekly
Bvf Inc/Il Now Owns 12949229 Shares In Regulus Therapeutics Inc. (RGLS) - Post Analyst

Regulus Therapeutics' (RGLS) CEO Paul Grint on Q1 2017 Results - Earnings Call ...
Seeking Alpha - May 7, 2017
As part of this restructuring, I have made the decision to resign as President, CEO and the Director of Regulus. When I joined Regulus almost 3 years ago, I was excited by the size of microRNAs. Today, as I leave the company, and based on our ...

Enter a stock symbol to view the stock details.